AU
UK
CA
US
IND
NZ
Last update at 2026-06-08T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
Thu 22 May 25, 01:18 PMMedical Devices & Supplies - Specialty Stocks Q1 Highlights: Enovis (NYSE:ENOV)
Fri 16 May 25, 03:31 AMHAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Mon 12 May 25, 12:40 PMHaemonetics Corporation Just Beat EPS By 8.7%: Here's What Analysts Think Will Happen Next
Sun 11 May 25, 02:08 PMShould You Be Adding Haemonetics (NYSE:HAE) To Your Watchlist Today?
Sat 10 May 25, 02:00 PMHaemonetics Full Year 2025 Earnings: EPS Beats Expectations
Sat 10 May 25, 01:54 PMHere's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
Sat 10 May 25, 12:30 AM1 Healthcare Stock to Consider Right Now and 2 to Brush Off
Fri 09 May 25, 04:35 AMHaemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Thu 08 May 25, 01:20 PM| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Income before tax | 212.07M | 151.87M | 141.40M | 63.63M | 72.91M |
| Minority interest | - | - | - | - | - |
| Net income | 167.68M | 117.56M | 115.40M | 43.38M | 79.47M |
| Selling general administrative | 414.35M | 413.72M | 376.68M | 339.56M | 274.19M |
| Selling and marketing expenses | 7.70M | 7.10M | - | - | - |
| Gross profit | 778.55M | 711.91M | 615.10M | 505.50M | 397.84M |
| Reconciled depreciation | 115.59M | 97.22M | 93.31M | 97.75M | 84.29M |
| Ebit | 247.10M | 206.84M | 156.03M | 80.75M | 57.96M |
| Ebitda | 355.99M | 295.45M | 249.34M | 169.47M | 142.25M |
| Depreciation and amortization | 108.89M | 88.61M | 93.31M | 88.72M | 84.29M |
| Non operating income net other | - | - | -14.63000M | -17.12100M | -16.83400M |
| Operating income | 221.82M | 164.88M | 156.03M | 80.75M | 57.96M |
| Other operating expenses | 1139.01M | 1144.17M | 459.06M | 921.47M | 812.50M |
| Interest expense | 9.75M | 13.02M | 14.63M | 17.12M | 16.83M |
| Tax provision | 44.39M | 34.31M | 26.00M | 20.25M | -6.55600M |
| Interest income | 9.75M | 13.02M | 14.63M | 17.12M | 16.83M |
| Net interest income | -9.74600M | -13.01800M | -14.63000M | -17.12100M | -16.83400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | 0.58M | 1.03M |
| Other items | - | - | - | - | - |
| Income tax expense | 44.39M | 34.31M | 26.00M | 20.25M | -6.55600M |
| Total revenue | 1360.82M | 1309.06M | 1168.66M | 993.20M | 870.46M |
| Total operating expenses | 556.73M | 547.03M | 459.06M | 433.78M | 339.88M |
| Cost of revenue | 582.28M | 597.14M | 553.56M | 487.69M | 472.62M |
| Total other income expense net | -9.74600M | -13.01800M | -14.63000M | -17.12100M | 14.95M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 167.68M | 117.56M | 115.40M | 43.38M | 79.47M |
| Net income applicable to common shares | 167.68M | 117.56M | 115.40M | 43.38M | 79.47M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 2450.95M | 2195.59M | 1934.83M | 1859.73M | 1819.92M |
| Intangible assets | 455.74M | 406.12M | 275.77M | 310.26M | 365.48M |
| Earning assets | - | - | - | - | - |
| Other current assets | 60.41M | 66.34M | 46.73M | 44.13M | 51.07M |
| Total liab | 1630.11M | 1235.63M | 1116.83M | 1110.31M | 1088.25M |
| Total stockholder equity | 820.84M | 959.96M | 818.00M | 749.42M | 731.67M |
| Deferred long term liab | - | - | 36.20M | 28.73M | 43.83M |
| Other current liab | 164.21M | 185.55M | 145.89M | 137.92M | 159.91M |
| Common stock | 0.48M | 0.51M | 0.50M | 0.51M | 0.51M |
| Capital stock | 0.48M | 0.51M | 0.50M | 0.51M | 0.51M |
| Retained earnings | 352.17M | 360.46M | 253.17M | 202.39M | 157.98M |
| Other liab | - | - | - | 108.60M | 76.91M |
| Good will | 604.27M | 565.08M | 466.23M | 467.29M | 466.44M |
| Other assets | 0.00100M | 0.00000M | 58.80M | 67.67M | 17.04M |
| Cash | 306.76M | 178.80M | 284.47M | 259.50M | 192.31M |
| Cash and equivalents | 306.76M | 178.80M | 284.47M | 259.50M | 192.31M |
| Total current liabilities | 578.11M | 300.38M | 251.82M | 442.27M | 253.50M |
| Current deferred revenue | 43.35M | 31.24M | 30.21M | 31.83M | 26.27M |
| Net debt | 918.02M | 628.99M | 481.42M | 514.09M | 515.30M |
| Short term debt | 303.56M | 10.23M | 11.78M | 214.15M | 17.02M |
| Short long term debt | 303.56M | 10.23M | 11.78M | 214.15M | 17.02M |
| Short long term debt total | 1224.79M | 807.79M | 765.89M | 773.59M | 707.61M |
| Other stockholder equity | 523.26M | 634.63M | 594.71M | 572.48M | 602.73M |
| Property plant equipment | 331.54M | 366.63M | 310.88M | 258.48M | 277.42M |
| Total current assets | 934.98M | 768.90M | 769.72M | 756.03M | 693.55M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | 76.00M | -28.12400M | -100.25700M |
| Short term investments | - | 1.67M | - | - | - |
| Net receivables | 202.66M | 206.56M | 179.14M | 159.38M | 127.56M |
| Long term debt | 921.23M | 797.56M | 754.10M | 559.44M | 690.59M |
| Inventory | 365.14M | 317.20M | 259.38M | 293.03M | 322.61M |
| Accounts payable | 67.00M | 73.36M | 63.93M | 58.37M | 50.29M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -55.08400M | -35.63200M | -30.38100M | -25.95400M | -29.54700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.50M | 0.51M | 0.51M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | 253.17M | 202.39M | 157.98M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 164.11M | 81.12M | 106.97M | 63.20M | 76.89M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1515.97M | 1426.69M | 1165.10M | 1103.70M | 1126.38M |
| Capital lease obligations | - | - | - | 7.20M | 70.67M |
| Long term debt total | 921.23M | 797.56M | 754.10M | 559.44M | 690.59M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Investments | -161.89500M | -322.38900M | -143.78800M | -86.34500M | -425.44200M |
| Change to liabilities | - | - | 39.82M | 7.64M | -56.42200M |
| Total cashflows from investing activities | -161.89500M | -322.38900M | -143.78800M | -86.34500M | -425.44200M |
| Net borrowings | 447.31M | 37.75M | 269.26M | -17.50000M | 370.73M |
| Total cash from financing activities | 108.82M | 38.16M | -100.36400M | -15.74900M | 367.45M |
| Change to operating activities | - | - | - | -4.51000M | -4.65000M |
| Net income | 167.68M | 117.56M | 115.40M | 43.38M | 79.47M |
| Change in cash | 127.96M | -105.66600M | 24.97M | 67.19M | 54.99M |
| Begin period cash flow | 178.80M | 284.47M | 259.50M | 192.31M | 137.31M |
| End period cash flow | 306.76M | 178.80M | 284.47M | 259.50M | 192.31M |
| Total cash from operating activities | 181.72M | 181.75M | 273.06M | 172.26M | 108.81M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 115.59M | 97.22M | 93.31M | 97.75M | 84.29M |
| Other cashflows from investing activities | -15.00200M | -13.74100M | -0.39200M | 10.16M | -388.40200M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -64.70400M | -60.06100M | 30.75M | 24.31M | -38.90900M |
| Change to account receivables | 6.96M | -24.19300M | -24.42100M | -34.97400M | 44.12M |
| Sale purchase of stock | -225.00000M | -5.88500M | -75.00000M | 6.55M | 10.23M |
| Other cashflows from financing activities | -113.49400M | -6.80700M | -15.73900M | 1.75M | 449.33M |
| Change to netincome | - | - | 36.21M | 46.32M | 4.73M |
| Capital expenditures | 39.28M | 66.30M | 110.19M | 96.51M | 37.04M |
| Change receivables | - | - | -24.42100M | -34.97400M | 44.12M |
| Cash flows other operating | - | - | -19.98200M | -22.61600M | -33.42400M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 28.91M | 70.17M | 50.81M |
| Change in working capital | -101.96200M | -74.70100M | 25.50M | -15.17700M | -59.68200M |
| Stock based compensation | 29.64M | 28.33M | 25.58M | 24.36M | 25.52M |
| Other non cash items | -23.99500M | 24.39M | 8.48M | 16.95M | -0.91900M |
| Free cash flow | 142.45M | 115.45M | 162.87M | 75.75M | 71.77M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HAE Haemonetics Corporation |
3.60 5.05% | 74.88 | 16.59 | 11.22 | 2.14 | 3.12 | 2.81 | 10.18 |
| ABT Abbott Laboratories |
0.88 0.97% | 91.38 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
-4.13 1.35% | 301.53 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
1.23 1.52% | 81.92 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
0.15 0.31% | 48.70 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
125 Summer Street, Boston, MA, United States, 02110
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher A. Simon | CEO, Pres & Director | 1964 |
| Mr. Josep Lluis Llorens | Exec. VP of Global Manufacturing & Supply Chain | 1963 |
| Mr. Stewart W. Strong | Pres of Global Hospital | 1967 |
| Mr. James C. D'Arecca CPA | CFO, Exec. VP & Financial Officer | 1971 |
| Ms. Farris Maryanne Maunsell | VP, Chief Accounting Officer & Principal Accounting Officer | 1975 |
| Ms. Anila Lingamneni | Exec. VP & CTO | 1968 |
| Ms. Olga Guyette | Director of Investor Relations | NA |
| Carla Burigatto | VP of Communications | NA |
| Mr. Francis Tan | Sr. VP of Corp. Devel. & Planning | NA |
| Ms. Laurie A. Miller | Sr. VP & Chief HR Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...